Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

18.7K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.7K
Affinity and Avidity01:41

Affinity and Avidity

40.7K
Overview
40.7K
Antibody Structure01:10

Antibody Structure

69.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
69.4K
Cross-reactivity00:42

Cross-reactivity

34.0K
Overview
34.0K
Antibody Actions01:26

Antibody Actions

4.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a recombinant single-cycle influenza viral vector as an intranasal vaccine against SARS-CoV-2.

Scientific reports·2026
Same author

mRNA delivery of a class 1/4 SARS-CoV-2 neutralizing antibody protects against diverse sarbecoviruses in a lethal mouse challenge model.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Induction of broadly neutralizing HIV antibodies by a two-step mechanism informs vaccine design.

Science (New York, N.Y.)·2026
Same author

mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures.

Cell reports·2026
Same author

Bivalent mRNA booster encoding virus-like particles elicits potent polyclass receptor-binding domain antibodies in pre-vaccinated mice.

eLife·2026
Same author

Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332<sub>gp120</sub> glycan-independent epitope.

Nature immunology·2026
Same journal

Implications of HIV persistence and pathogenesis in microglia.

Current opinion in HIV and AIDS·2026
Same journal

Paediatric HIV cure section in Current Opinion in HIV and AIDS.

Current opinion in HIV and AIDS·2026
Same journal

Early intervention, lasting impact: benefits of early antiretroviral therapy and implications for posttreatment control.

Current opinion in HIV and AIDS·2026
Same journal

Natural killer cells in pediatric HIV cure strategies: from viral control to immunotherapeutics.

Current opinion in HIV and AIDS·2026
Same journal

Nonhuman primate models of HIV reveal reservoir dynamics and promising interventions.

Current opinion in HIV and AIDS·2026
Same journal

Impact of sex differences in adult and paediatric HIV-1 cure.

Current opinion in HIV and AIDS·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K

Antibody engineering for increased potency, breadth and half-life.

Stuart A Sievers1, Louise Scharf, Anthony P West

  • 1aDivision of Biology and Biological Engineering, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA 91125, USA bHoward Hughes Medical Institute, Chevy Chase, MD 20815-6789, USA.

Current Opinion in HIV and AIDS
|March 12, 2015
PubMed
Summary
This summary is machine-generated.

Antibody engineering enhances HIV-1 therapies by improving antibody potency and breadth. While some engineered antibodies show increased polyreactivity and shorter half-lives, new strategies are overcoming these challenges for better therapeutic outcomes.

More Related Videos

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

19.5K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

44.3K

Related Experiment Videos

Last Updated: Apr 16, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

18.5K
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
12:55

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

19.5K
Generation of Murine Monoclonal Antibodies by Hybridoma Technology
09:42

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

44.3K

Area of Science:

  • Immunology
  • Biotechnology
  • Virology

Background:

  • Monoclonal antibodies (mAbs) are crucial therapeutics due to their specificity, high affinity, and Fc-mediated effector functions.
  • Engineering antibodies aims to improve their therapeutic properties for various diseases, including HIV-1 infection.

Purpose of the Study:

  • To review recent advancements in HIV-1 antibody engineering.
  • To discuss the impact of increased polyreactivity on the serum half-lives of engineered antibodies.
  • To explore strategies for overcoming challenges in antibody engineering for HIV-1 therapy.

Main Methods:

  • Bioinformatics analysis of antibody sequences and efficacies.
  • Structural characterization of anti-HIV-1 antibodies.
  • In vivo studies to assess antibody performance.
  • Review of targeted and library-based antibody engineering approaches.

Main Results:

  • Recent studies have elucidated the relationship between antibody sequences and anti-HIV-1 efficacy.
  • Engineered antibodies show potential for enhanced breadth and potency.
  • Increased polyreactivity in some engineered antibodies can lead to shorter serum half-lives, but solutions are emerging.

Conclusions:

  • Antibody engineering offers promising strategies to improve the therapeutic potential of anti-HIV-1 antibodies.
  • Addressing polyreactivity and serum half-life issues is key to successful antibody-based HIV-1 therapies.
  • Advances in bispecific antibody design further enhance therapeutic options for HIV-1.